SELENA+ RECEIVES REGULATORY APPROVAL IN INDONESIA

Jan 2021 – In Indonesia, it is estimated that nearly 16 million adults to be living with type 2 diabetes. More worringly, experts estimate more than half of diabetes cases in Indonesia remain undiagnosed, especially among young people. Every is at risk of going blind. Around a third of diabetics develop some form of eye health complication and is at risk of going blind if it is not detected and treated early.

To add to this fast-growing challenge, there is a general lack of awareness for the need for eye screening and trained resources dedicated to this segment of healthcare. Having an artificial intelligence system to detect and prioritise treatment for diabetic retinopathy would greatly benefit a country like Indonesia.

Recently, SELENA+ our deep learning system to detect diabetic retinopathy, glaucoma and age-related macular degeneration received regulatory approval from Kementerian Kesihatan Republik Indonesia (Ministry of Health, Indonesia) to deploy the software in Indonesia.

With the approval, EyRIS intends to collaborate with relevant public agencies and the private sector to contribute to the development of an efficient and safe screening system in Indonesia.

 

About EyRIS

EyRIS develops and deploys artificial intelligence systems to automatically screen retinal images for diabetic retinopathy, glaucoma and age-related macular degeneration – diseases that lead to preventable blindness. Jointly developed by the Singapore Eye Research Institute and National University of Singapore, the technology can significantly reduce public health care cost while maintaining standard of care.

 


Please direct all queries related to this article to Marketing at enquiry@nova-hub.com